MT Pharma develops and provides pharmaceuticals and healthcare products. The company is involved in the research and manufacturing of various medical treatments.

MT Pharma

Mitsubishi Tanabe Pharma Corporation | 3,016 followers on LinkedIn. 

CMC & Regulatory Strategy | Subject Matter Expert | Regulatory Compliance | Regulatory submissions | Regulatory Intelligence Hub |

Seema Singh シング シーマ

Mitsubishi Tanabe Pharma Corporation

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

DNSSEC

Quality

Nozomi Ando

Director, Neurology Group, Global Product Strategy Department

Tsuyoshi Okuno

Business Management

Egawa Hiro

Assistant Manager (Project Management)

Isolde Delic

Healthcare

Janine Sampong

Eiji Tanaka

Sales and Support

Janice Hsu

Deputy General Manager

Joanne Plumb

President

Ueno Hiroaki

Engineering

Yasuhiro Fujino

Seiichi Murakami

Eizo Tabaru

Shigehiko Hattori

Takashi Kobayashi

Shigeki Iwane

Yoshiaki Ishizaki

Michihiro Tsuchiya

Senior Managing Executive Officer & Division Manager of Research Division

Managing Executive Officer

Seiichi Kiso

General Manager, Business Development & Licensing Department

Takashi Tanaka

Executive Officer

Hiroaki Ueno

Founder & President

Kenichi Yanagisawa

Corporate Auditor

Koji Kudo

Mark Paskewitz

Director, Clinical Science

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat

Asia-Pacific (APAC) Public Companies With More Than 500 Employees (Top 10K)

Asia Pharmaceutical Companies

Asia-Pacific (APAC) Biotechnology Public Companies

Companies That Exited in 1999

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” 

As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Osaka

Japan

Asia

Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma discloses BRD4 degradation inducers

Astrazeneca and Mitsubishi Tanabe Pharma jointly develop NLRP3 inflammasome inhibitors

Systemic Sclerosis Market to Exhibit Significant Growth by 2034, Predicts DelveInsight | Key Companies - Kyowa ...

Novartis v. Mitsubishi Tanabe

Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key ...

EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan

News - Focus On, MT-2766

Pricing, Policy and Regulation - Mitsubishi Tanabe Pharma

An ALS treatment drug that slows disease progression, available as an intravenous injection.

A vesicular monoamine transporter 2 inhibitor used for tardive dyskinesia.

A humanized anti-CD19 monoclonal antibody for treating neuromyelitis optica spectrum disorder.

An OTC medication for scalp itch and dryness, containing heparin-like substances for moisturizing.

An OTC medication for hand roughness due to water work, containing heparin-like substances for moisturizing.

A gene therapy product for peripheral artery disease, though its sales rights have been returned to AnGes.

United States

North America

South Korea

India

Taiwan

Microsoft Outlook

Office 365

Apache Server

Mitsubishi Tanabe Pharma owns Mitsubishi Tanabe Pharma America

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:59 PM	42627d76
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:59 PM	f2f229ef
crunchbase trigger	general	Nov 17, 2024 8:59 PM	000d3729
crunchbase profile	general	Nov 17, 2024 9:05 PM	0066c7d8
li profile	general	Nov 17, 2024 8:59 PM	bee2f193
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	83f01564
peers	general	Nov 17, 2024 8:59 PM	9f87bf94
news basic	general	Nov 17, 2024 8:59 PM	9d78957f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CO

JP:CO:MT-PHARMA

MT Pharma